MiniMed Group, Inc.
18.34USD
+0.0500 (+0.27%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on MMED.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.1▼ | $0.14 | 0 | 3 |
| Next quarter | $0.21▲ | $0.16 | 5 | 0 |
| Current year | $0.7▲ | $0.63 | 1 | 0 |
| Next year | $0.69▲ | $0.66 | 2 | 2 |
Beat in 1 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.1 | $0.13 | +0.04 (+37.8%) |
| 2026-04-30 | -$0.22 | -$0.6 | -0.38 (-171.8%) |
| 2026-01-31 | $0.21 | $0.08 | -0.13 (-63.7%) |
25 ratings from 14 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Jefferies | Initiated | Hold | $22 | Oct 12, 2026 |
| Mizuho | Maintained | Outperform | $26 $28 | Oct 8, 2026 |
| Barclays | Initiated | Equal-Weight | $22 | Oct 7, 2026 |
| Truist Securities | Initiated | Buy | $29 | Sep 24, 2026 |
| Morgan Stanley | Maintained | Overweight | $19 $21 | Sep 3, 2026 |
| Citigroup | Maintained | Buy | $23 $26 | Sep 2, 2026 |
| Evercore ISI Group | Maintained | Outperform | $20 $27 | Sep 2, 2026 |
| Wells Fargo | Maintained | Overweight | $22 $26 | Sep 2, 2026 |
| UBS | Maintained | Buy | $25 $28 | Sep 2, 2026 |
| Mizuho | Maintained | Outperform | $21 $26 | Sep 2, 2026 |
| B of A Securities | Maintained | Buy | $24 $28 | Sep 2, 2026 |
| BTIG | Maintained | Buy | $25 $28 | Sep 1, 2026 |
| Wells Fargo | Maintained | Overweight | $26 $22 | Jun 4, 2026 |
| B of A Securities | Maintained | Buy | $27 $20 | May 18, 2026 |
| Benchmark | Initiated | Buy | $20 | May 12, 2026 |
| Barclays | Initiated | Overweight | $26 | Apr 1, 2026 |
| William Blair | Initiated | Outperform | — | Mar 31, 2026 |
| Citigroup | Initiated | Buy | $23 | Mar 31, 2026 |
| Piper Sandler | Initiated | Neutral | $16 | Mar 31, 2026 |
| Mizuho | Initiated | Outperform | $21 | Mar 31, 2026 |
| Wells Fargo | Initiated | Overweight | $26 | Mar 31, 2026 |
| Morgan Stanley | Initiated | Overweight | $19 | Mar 31, 2026 |
| Evercore ISI Group | Initiated | Outperform | $20 | Mar 31, 2026 |
| B of A Securities | Initiated | Buy | $27 | Mar 31, 2026 |
| BTIG | Initiated | Buy | $25 | Mar 31, 2026 |
29 filings from 20 insiders · 0 buy / 0 sell over 6m
Officers and directors of MMED, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dianaty AliOfficer, EVP Ch. Prod. & Tech Officer | Grant | 11.1k | — | — | Oct 15, 2026 |
| Chandrasena GillianOfficer, SVP, Chief HR Officer | Grant | 1.8k | — | — | Oct 15, 2026 |
| Lofton Kevin EDirector | Grant | 836 | — | — | Oct 15, 2026 |
| Bricker AmyDirector | Grant | 11.9k | — | — | Oct 15, 2026 |
| Hopkins Robert (Bob)Director | Grant | 11.9k | — | — | Oct 15, 2026 |
| Endicott David J.Director | Grant | 3.4k | — | — | Oct 15, 2026 |
| Medtronic plc10% owner | Other | 252.81M | — | — | Oct 15, 2026 |
| Endicott David J.Director | Grant | 11.8k | — | — | Oct 9, 2026 |
| Lofton Kevin EDirector | Grant | 11.8k | — | — | Oct 9, 2026 |
| Wicks Timothy ADirector | Grant | 11.8k | — | — | Oct 9, 2026 |
| EISENBERG GLENN ADirector | Grant | 11.8k | — | — | Oct 9, 2026 |
| GROSSMAN D KEITHDirector | Grant | 11.8k | — | — | Oct 9, 2026 |
| Denton Sheila A.Officer, SVP, Gen. Counsel & Corp. Sec. | Grant | 58.9k | — | — | Oct 1, 2026 |
| SPOONER CHADChief Financial Officer | Grant | 116.6k | — | — | Jul 1, 2026 |
| WILLS COURTNEY NELSONGeneral Counsel | Grant | 82.8k | — | — | Jul 1, 2026 |
| DIANATY ALIOfficer | Grant | 131.3k | — | — | Jul 1, 2026 |
| CHANDRASENA GILLIANOfficer | Grant | 44.2k | — | — | Jul 1, 2026 |
| GYURCI JOHNOfficer | Grant | 24.2k | — | — | Jul 1, 2026 |
| DALLARA QUEChief Executive Officer | Grant | 297.6k | — | — | Jul 1, 2026 |
| SPOONER CHADChief Financial Officer | Grant | 269.4k | — | — | Mar 11, 2026 |
No analyst notes on MMED yet.
Members whose judged calls on MMED have played out most reliably.
No settled calls on MMED yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 12 | 3 | 0 | 1 | Buy2.38 |
| 1 mo ago | 1 | 10 | 1 | 0 | 1 | Buy2.23 |
| 2 mo ago | 1 | 10 | 1 | 0 | 1 | Buy2.23 |
| 3 mo ago | 1 | 10 | 1 | 0 | 0 | Buy2.00 |